Table 1 Trials' Characteristics.
Authors | Pts | Dose RT (Gy) | Arms (mo.) | Median F.U. | End-Points | Median PSA (ng/mL) | N° of pts (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Primary | Secondary | Â | Gleason Score 7-10 | T3-T4 |
Laverdiere et al | 148 148 | 64 | 5 (AS) 10 (AS) | 3.7 yrs | BDFS, CDFS | - | 11.9 12.7 | 82 (27.6) | 40 (13.4) |
Crook et al | 177 184 | 66 | 3 (GF) 8 (GF) | 79 mo. | OS, CSS, DFS | - | 8.9 10.1 | 178 (49.3) | 48 (13.2) |
Horwitz et al | 763 758 | 65-70 | 4 (GF) 24 (GF) | 10 yrs | DFS | OS, BF, DMF | 20.8 19.8 | 838 (55.1) | 829 (54.5) |
Bolla et al | 483 487 | 70 | 6 (CAB) 36 (CAB) | 5.2 yrs | OS, CPFS, DS, BPFS | - | 18.8 18.8 | 479 (49.3) | 754 (77.7) |
Armstrong et al | 127 134 | 50-74 | 4 (CAB) 8 (CAB) | 102 mo. | BF | OS, CSS | 17.0 13.6 | 153 (55.4) | 159 (57.6) |